Vistin Pharma is strongly committed to maintaining an open dialogue with our shareholders, potential investors, analysts, investment banks and the financial markets.

Our goal is for the share price to reflect the underlying value of the company by providing all price-relevant information to the market.
Last updated 29.03 2022 11:00
Nok 16,80
Since open-0,30 (-1.70%)
Since previous close +0,44 (+2.60%)

8 reasons for investing in Vistin Pharma ASA.

Leading Producer
Amongst Top 5 producers of metformin HCl globally
High Quality Reputation
Leading reputation as producer of high quality APIs with strong track record of customer delivery
Attractive Market Dynamics
Established position in growing metformin market
Diverse Client Portfolio
Established client base comprising mix of Big Pharma and leading generics players
Sustained Revenue Growth
Strong growth profile with double digit revenue growth in the last 5 years
Advanced Manufacturing Facilities
State of the art and dedicated manufacturing facility with potential for further expansion
Strong Leadership
Experienced management team with a strong track record
A Front-runner
Leading the ESG culture in the industry

Annual General Meeting 2025

Download resources

Quarterly Results

Annual Reports

Other downloads

Investor calendar

16.2.24
Q4 2023 Quarterly report
24.4.24
2023 Annual Report
24.4.24
Q1 Quarterly report
23.5.24
Annual General Meeting
23.8.24
Q2 and Half-Yearly report
31.10.24
Q3 Quarterly Report

Main shareholders

Per May 15th 2025

NAME

SHAREHOLDING

% SHARE

1
INTERTRADE SHIPPING AS*
14 509 280
32,72 %
2
HOLMEN SPESIALFOND
4 371 558
9,86 %
3
PACTUM VEKST AS*
2 991 773
6,75 %
4
MP PENSJON PK
1 719 848
3,88 %
5
STORKLEIVEN AS
751 000
1,69 %
6
AUGUST RINGVOLD AGENTUR AS
750 315
1,69 %
7
LUCELLUM AS
720 000
1,62 %
8
HENRIK MIDTTUN HAAVIE
706 253
1,59 %
9
TIGERSTADEN AS
650 000
1,47 %
10
IVAR LØGES STIFTELSE
540 000
1,22 %
11
SURFSIDE HOLDING AS
527 960
1,19 %
12
CORTEX AS
508 989
1,15 %
13
SANDEN EQUITY AS
500 000
1,13 %
14
TOM RAGNAR PRESTEGÅRD STAAVI
500 000
1,13 %
15
DNB BANK ASA
499 602
1,13 %
16
DELTA AS
410 000
0,92 %
17
GINKO AS
400 000
0,90 %
18
ØYSTEIN STRAY SPETALEN
323 650
0,80 %
19
MELESIO INVEST AS
309808
0,70 %
20
NIELS CATO BECKETT AALL
301658
0,68 %
Total 20 largest shareholders
31 991 694
72,14 %
Other shareholders
12 352 898
27,86 %
Total number of shares
44 344 592
100%
* Board members of Vistin Pharma, or companies controlled by Board members
Vistin Pharma - Oslo Stock Exchange

Contact

Alexander Karlsen
CFO
Vistin Pharma ASA
+47 970 53 621alexander.karlsen@vistin.com
Alexander Karlsen